Latest Manufacturing Technology News

AdAlta, Oribiotech, and Cell Therapies have inked a Memorandum of Understanding to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and Asia Pacific, aiming to slash costs and boost production speed for CAR-T therapies.

Amaero Ltd (ASX:3DA) has signed a Master Purchasing Agreement worth A$7.8 million for titanium alloy powders, underpinning plans to double production in FY2027 amid strong demand across multiple sectors.

6K Additive has landed a $1.1 million order for its Nickel 718 superalloy powder from a major OEM, underscoring rising demand for advanced metal powders in additive manufacturing across key industries.

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

AML3D has landed a nearly $10 million order for four ARCEMY X 6700 systems from Newport News Shipbuilding, expanding its footprint in the US defence manufacturing sector.

BluGlass has embarked on a A$1.25 million development program with a major US defence prime, receiving an initial A$560,000 order to develop cutting-edge visible GaN lasers for aerospace and defence applications.

BrainChip has launched its AKD2500 silicon development project, advancing its Akida™ 2.0 neuromorphic AI platform with a $2.5 million investment and prototype expected by Q3 2026.

Amaero Ltd reported a remarkable 367% revenue increase to A$7.76 million for H1 FY2026, supported by a $50 million capital raise and exclusive supply agreements with industry leaders. Despite widening losses, the company is accelerating capacity expansion and securing key partnerships in aerospace and defence.

Titomic Limited has secured a Space Act Agreement with NASA to evaluate its innovative cold spray additive manufacturing technology for aerospace applications, marking a significant step into the space sector.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.

Titomic has made significant strides in transitioning from development to production, securing key contracts in defense and semiconductor sectors while maintaining a strong cash position.

SRJ Technologies has completed the first phase of its growth strategy and is now advancing into market penetration with a significant $23.8 million joint venture in the Middle East and a key board appointment.